Search

CN-121987595-A - Rhizoma phragmitis sustained-release preparation for hyperuricemia and preparation method thereof

CN121987595ACN 121987595 ACN121987595 ACN 121987595ACN-121987595-A

Abstract

The invention belongs to the technical field of pharmacy, and in particular relates to a reed rhizome slow release preparation for hyperuricemia and a preparation method thereof, wherein the reed rhizome slow release preparation for hyperuricemia comprises, by weight, 80-100 parts of reed rhizome extract, 160-200 parts of functional reed rhizome powder, 0.01-0.1 part of freeze-dried powder, 40-65 parts of quercetin and 30-50 parts of acrylic resin, the reed rhizome extract and the quercetin can synergistically regulate uric acid metabolism in an omnibearing manner, the introduction of the freeze-dried powder not only realizes the real-time visual monitoring of drug release progress, but also can promote the targeting affinity of the preparation to intestinal mucosa and joint parts, so that the blood uric acid level quickly tends to be stable and maintained for a long time, after colon target positioning slow release pellets and quercetin quick release pellets are mixed, the quick release pellets can quickly disintegrate and release quercetin to realize quick acid control, and the slow release pellets accurately deliver drugs in colon and continuously release active ingredients to realize long-acting stable acids.

Inventors

  • WEI XIAOQING
  • LI MING
  • LIU YINHUI

Assignees

  • 大连医科大学

Dates

Publication Date
20260508
Application Date
20260318

Claims (7)

  1. 1. The reed rhizome slow release preparation for hyperuricemia is characterized by comprising the following raw materials, by weight, 80-100 parts of reed rhizome extract, 160-200 parts of functional reed rhizome powder, 0.01-0.1 part of freeze-dried powder, 40-65 parts of quercetin and 30-50 parts of acrylic resin; The freeze-dried powder comprises the following raw materials in mass ratio of citric acid monohydrate, L-arginine, mannooligosaccharide=2:1-1.5:0.01; The preparation method of the freeze-dried powder comprises the following steps: (1) Weighing citric acid monohydrate and L-arginine, adding the citric acid monohydrate and the L-arginine into purified water, magnetically stirring the mixture to obtain a mixed solution, adding mannooligosaccharide into the mixed solution, and stirring the mixed solution to obtain a carbon dot precursor solution; (2) Regulating the pH value of the carbon dot precursor solution, stirring, standing, performing solvothermal reaction, and cooling to room temperature to obtain a mannooligosaccharide modified carbon dot solution; (3) Dialyzing and purifying the mannooligosaccharide modified carbon dot solution to obtain a purified carbon dot solution; (4) And freeze-drying the purified carbon dot solution, cooling to room temperature, crushing, and sieving to obtain freeze-dried powder.
  2. 2. The reed rhizome sustained release preparation for hyperuricemia according to claim 1, wherein in the step (1), the ratio of citric acid monohydrate to purified water is 1g:25-35mL.
  3. 3. The reed rhizome sustained release preparation for hyperuricemia according to claim 1, wherein in the step (4), the freeze-drying process is that pre-freezing is performed for 4 hours at-40 ℃, then sublimation drying is performed, the sublimation temperature is set to be-10 ℃, the sublimation drying is performed for 8 hours, after the sublimation drying is completed, the analysis drying is performed, and the analysis drying time is 4 hours.
  4. 4. The reed rhizome sustained release preparation for hyperuricemia according to claim 1, wherein the preparation process of the reed rhizome extract comprises the steps of taking dry rhizome of reed, washing, drying, crushing and sieving to form rhizome powder, adding the rhizome powder into a mixed solvent according to a feed liquid ratio of 1:20, reflux extracting, cooling, filtering, concentrating under reduced pressure, and freeze drying to obtain the reed rhizome extract.
  5. 5. The reed rhizome slow release preparation for hyperuricemia according to claim 1, wherein the preparation process of the functional reed rhizome powder comprises the steps of taking dry reed rhizome, pre-cooling by liquid nitrogen, superfine grinding, sieving to obtain superfine powder, placing the superfine powder into sodium hydroxide solution, stirring, washing, drying, slightly grinding again, and sieving to obtain the functional reed rhizome powder.
  6. 6. A method for preparing a sustained-release formulation of reed rhizome for hyperuricemia according to any one of claims 1 to 5, comprising the steps of: S1, taking freeze-dried powder, dissolving the freeze-dried powder in purified water, carrying out ultrasonic treatment under ice bath to obtain carbon dot stock solution, weighing HPMC solution, and mixing the HPMC solution and the carbon dot stock solution in a dark place to obtain a composite adhesive; S2, mixing the reed rhizome extract with functional reed rhizome powder to obtain a drug-loaded powder mixture, taking a microcrystalline cellulose pellet core, and coating the drug-loaded powder mixture on the surface of the microcrystalline cellulose pellet core by using a composite adhesive by adopting a fluidized bed powder lamination process to obtain drug-loaded pellets; S3, dissolving acrylic resin in isopropanol, adding triethyl citrate and talcum powder, stirring and homogenizing to obtain coating liquid, and spray-coating the coating liquid on the surface of the drug-loaded pellets to obtain colon-specific sustained-release pellets; S4, taking quercetin, preparing quercetin quick-release pellets, uniformly mixing colon-specific sustained-release pellets and quercetin quick-release pellets to obtain mixed pellets, filling the mixed pellets into a hard capsule shell, and packaging with aluminum plastic to obtain the reed rhizome sustained-release preparation for hyperuricemia.
  7. 7. The method for preparing a sustained-release formulation of reed rhizome for hyperuricemia according to claim 6, wherein in step S1, the dosage ratio of the lyophilized powder to the purified water is 1mg:2-5mL; in the step S4, the mass ratio of the colon-specific sustained-release pellets to the quercetin quick-release pellets is 2:1.

Description

Rhizoma phragmitis sustained-release preparation for hyperuricemia and preparation method thereof Technical Field The invention belongs to the technical field of pharmacy, and in particular relates to a reed rhizome sustained-release preparation for hyperuricemia and a preparation method thereof. Background Hyperuricemia is a high-incidence chronic metabolic disease, and along with the change of life style and dietary structure of people, the prevalence rate of the disease is rapidly increased, and complications such as gout, kidney stones, liver and kidney injury and the like can be caused when the disease is serious, so that the daily life quality of patients is obviously affected. At present, the clinical preparations for hyperuricemia are various, and the preparations mainly comprise common tablets, capsules, powder and other conventional preparations and partial slow-release and targeting preparations from the aspect of the types of the preparations. Among them, the preparation using natural plant extract as active ingredient is widely focused because of high safety and small side effect, and reed rhizome as a traditional natural medicinal material has natural effects of inhibiting uric acid synthesis, promoting uric acid excretion, anti-inflammatory and protecting liver and kidney, and has been proved to be used for the adjuvant treatment of hyperuricemia. However, the hyperuricemia preparation based on reed rhizome extract still has a plurality of technical defects which are difficult to overcome in the prior art, on one hand, the existing preparation is mostly a single-component conventional preparation, and lacks reasonable component synergistic design, and only depends on single action of reed rhizome extract, so that the problems of single uric acid reducing mechanism, unbalanced effect and limited anti-inflammatory effect exist, on the other hand, the existing preparation mostly adopts a common preparation process, and lacks targeted slow release and targeting design, so that long-acting stable acid control cannot be realized, and meanwhile, the bioavailability of the medicine is lower, so that the treatment effect is further influenced. Therefore, development of a novel reed rhizome slow release preparation is needed to realize synchronous improvement of uric acid reducing curative effect, medication safety and in-vivo controllability, and provide better preparation selection for treating hyperuricemia. Disclosure of Invention Aiming at the defects of the prior art, the invention provides a reed rhizome slow release preparation for hyperuricemia and a preparation method thereof. The preparation can realize synergistic uric acid reduction, has the characteristics of oral safety, accurate targeting and good slow release effect, solves the technical problems that the traditional hyperuricemia treatment preparation is poor in uric acid reduction effect, poor in targeting and safety, can not realize long-acting slow release, rapid acid control synergy and poor suitability, meets the long-term treatment requirement of hyperuricemia, simultaneously provides a corresponding preparation method, has simple process and strong repeatability, is convenient for industrial production, and has higher practical value and application prospect. Aiming at the defects of the prior art, the invention adopts the following technical scheme: The invention provides a reed rhizome slow release preparation for hyperuricemia, which comprises the following raw materials, by weight, 80-100 parts of reed rhizome extract, 160-200 parts of functional reed rhizome powder, 0.01-0.1 part of freeze-dried powder, 40-65 parts of quercetin and 30-50 parts of acrylic resin; the freeze-dried powder comprises the following raw materials in mass ratio of citric acid monohydrate, L-arginine, mannooligosaccharide=2:1-1.5:0.01; The preparation method of the freeze-dried powder comprises the following steps: (1) Weighing citric acid monohydrate and L-arginine, adding the citric acid monohydrate and the L-arginine into purified water, wherein the dosage ratio of the citric acid monohydrate to the purified water is 1g:25-35mL, magnetically stirring the mixture for 20min to completely dissolve the mixture to obtain a mixed solution, adding mannooligosaccharide into the mixed solution, and magnetically stirring the mixed solution for 30min to obtain a carbon dot precursor solution; (2) Slowly dripping a pharmaceutical grade sodium hydroxide solution into a carbon dot precursor solution, continuously stirring, regulating the pH value of the solution to 5.5-6.0, standing for 5min after stirring uniformly, slowly transferring the solution into a polytetrafluoroethylene reaction kettle, sealing the reaction kettle, checking the tightness, ensuring no leakage, putting the sealed reaction kettle into a blast drying box, setting the temperature rising rate to be 5 ℃ per min, slowly rising the temperature to 180 ℃, reacting for 4h, naturally cooling to r